Trending at Lumira Ventures

Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments

Alyssia Watkin Portfolio News, Iterion Therapeutics

Iterion Therapeutics, an oncology-focused biopharmaceutical company developing small molecule inhibitors of Transducin beta-like protein 1 (TBL1), a downstream target in the Wnt/beta-catenin signaling pathway, announced today it is actively enrolling a Phase 1b/2a clinical trial of its lead molecule, tegavivint, in …

Iterion Therapeutics Announces Initiation of Phase 1/2 Clinical Trial to Study Tegavivint in Pediatric Cancers

Alyssia Watkin Portfolio News, Iterion Therapeutics

Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the initiation of a Phase 1/2 clinical trial to investigate tegavivint as a potential treatment for pediatric cancers, including sarcomas, lymphomas and other solid tumors that …

Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Acute Myeloid Leukemia

Alyssia Watkin Portfolio News, Iterion Therapeutics

Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the initiation of a Phase 1 clinical trial to investigate tegavivint as a potential treatment for acute myeloid leukemia (AML). This investigator-initiated trial is being led …

Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in Patients with Desmoid Tumors

Altamash Hashmi Portfolio News, Iterion Therapeutics

– Data provides springboard to advance three additional clinical programs evaluating Tegavivint in acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC) and pediatric cancers. HOUSTON, April 13, 2021 /PRNewswire/ — Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel …